Analyst Price Targets — CLPBY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 25, 2025 1:20 pm | — | Bernstein | $14.45 | $11.07 | TheFly | Coloplast price target raised to $14.45 from $13.50 at Bernstein |
Latest News for CLPBY
Coloplast A/S (CLPBY) Q3 2026 Earnings Call Transcript
Medical equipment maker Coloplast expects its Kerecis wound-care business to return to growth from January 2027 after changes to U.S. Medicare payments caused sales in outpatient settings to fall sharply, its finance chief told Reuters on Tuesday.
Coloplast remains a 'Buy,' trading ~20% below intrinsic value despite recent struggles and special charges. Organic growth was 6% in Q2-25/26, but reported results were impacted by a DKK 3 billion Kerecis impairment and currency headwinds. Management guides for 5–6% organic revenue growth and 5% EBIT growth in FY25/26, but targets 7–8% annual organic growth and 20%+ ROIC by FY29/30.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CLPBY.
Senate Trading
No Senate trades found for CLPBY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.